drugset / Trial / NCT01992328

IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency

NCT01992328

Phase 3 Unknown 30 enrolled Ajou University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

Immunoglobulin G deficiency subtypes in patients with asthma six months once a month intravenous immunoglobulin (400mg/kg/4weeks) infection in treatment-related effect on reducing the frequency of asthma exacerbations appreciate.

Timeline

Start
2013-12
Primary completion
2017-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Immune Globulin Intravenous (Human) Protein / enzyme biologic 400 mg/kg Intravenous

Indications